---
title: "Pentoxifylline - Peripheral Vascular Disease"
sidebar: mydoc_sidebar
permalink: db00806-mesh-d016491-1.html
toc: false 
---


Path ID: `DB00806_MESH_D016491_1`
{% include image.html url="images/db00806-mesh-d016491-1.png" file="db00806-mesh-d016491-1.png" alt="db00806-mesh-d016491-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/MESH:D010431">MESH:D010431 </a> | Pentoxifylline | Drug |
| <a href="https://identifiers.org/UniProt:Q14432">UniProt:Q14432 </a> | cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Protein |
| <a href="https://identifiers.org/MESH:D000242">MESH:D000242 </a> | Cyclic AMP | ChemicalSubstance |
| <a href="https://identifiers.org/reactome:R-HSA-2162123">reactome:R-HSA-2162123 </a> | Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | BiologicalProcess |
| <a href="https://identifiers.org/MESH:D013928">MESH:D013928 </a> | Thromboxane A2 | ChemicalSubstance |
| <a href="https://identifiers.org/GO:0070527">GO:0070527 </a> | Platelet aggregation | BiologicalProcess |
| <a href="https://identifiers.org/UniProt:Q13370">UniProt:Q13370 </a> | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Protein |
| <a href="https://identifiers.org/InterPro:IPR043371">InterPro:IPR043371 </a> | cAMP-specific 3',5'-cyclic phosphodiesterase 4 | GeneFamily |
| <a href="https://identifiers.org/UniProt:P29274">UniProt:P29274 </a> | Adenosine receptor A2a | Protein |
| <a href="https://identifiers.org/GO:0004016">GO:0004016 </a> | Adenylate cyclase activity | MolecularActivity |
| <a href="https://identifiers.org/GO:0010737">GO:0010737 </a> | Protein kinase A signaling | BiologicalProcess |
| <a href="https://identifiers.org/GO:0071159">GO:0071159 </a> | NF-kappaB complex | CellularComponent |
| <a href="https://identifiers.org/GO:0032612">GO:0032612 </a> | Interleukin-1 production | BiologicalProcess |
| <a href="https://identifiers.org/GO:0032635">GO:0032635 </a> | Interleukin-6 production | BiologicalProcess |
| <a href="https://identifiers.org/UniProt:P05362">UniProt:P05362 </a> | Intercellular adhesion molecule 1 | Protein |
| <a href="https://identifiers.org/UniProt:P19320">UniProt:P19320 </a> | Vascular cell adhesion protein 1 | Protein |
| <a href="https://identifiers.org/UniProt:P02741">UniProt:P02741 </a> | C-reactive protein | Protein |
| <a href="https://identifiers.org/GO:0006954">GO:0006954 </a> | Inflammatory response | BiologicalProcess |
| <a href="https://identifiers.org/MESH:D016491">MESH:D016491 </a> | Peripheral vascular disease | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Pentoxifylline | DECREASES ACTIVITY OF | Cgmp-Inhibited 3',5'-Cyclic Phosphodiesterase A |
| Pentoxifylline | DECREASES ACTIVITY OF | Cgmp-Inhibited 3',5'-Cyclic Phosphodiesterase B |
| Pentoxifylline | DECREASES ACTIVITY OF | Camp-Specific 3',5'-Cyclic Phosphodiesterase 4 |
| Cgmp-Inhibited 3',5'-Cyclic Phosphodiesterase A | DECREASES ABUNDANCE OF | Cyclic Amp |
| Cyclic Amp | NEGATIVELY REGULATES | Synthesis Of Prostaglandins (Pg) And Thromboxanes (Tx) |
| Synthesis Of Prostaglandins (Pg) And Thromboxanes (Tx) | INCREASES ABUNDANCE OF | Thromboxane A2 |
| Thromboxane A2 | POSITIVELY REGULATES | Platelet Aggregation |
| Platelet Aggregation | OCCURS IN | Peripheral Vascular Disease |
| Cgmp-Inhibited 3',5'-Cyclic Phosphodiesterase B | DECREASES ABUNDANCE OF | Cyclic Amp |
| Camp-Specific 3',5'-Cyclic Phosphodiesterase 4 | DECREASES ABUNDANCE OF | Cyclic Amp |
| Pentoxifylline | INCREASES ACTIVITY OF | Adenosine Receptor A2A |
| Adenosine Receptor A2A | POSITIVELY REGULATES | Adenylate Cyclase Activity |
| Adenylate Cyclase Activity | INCREASES ABUNDANCE OF | Cyclic Amp |
| Cyclic Amp | POSITIVELY REGULATES | Protein Kinase A Signaling |
| Protein Kinase A Signaling | NEGATIVELY REGULATES | Nf-Kappab Complex |
| Nf-Kappab Complex | POSITIVELY REGULATES | Interleukin-1 Production |
| Nf-Kappab Complex | POSITIVELY REGULATES | Interleukin-6 Production |
| Nf-Kappab Complex | INCREASES ACTIVITY OF | Intercellular Adhesion Molecule 1 |
| Nf-Kappab Complex | INCREASES ACTIVITY OF | Vascular Cell Adhesion Protein 1 |
| Nf-Kappab Complex | INCREASES ACTIVITY OF | C-Reactive Protein |
| Interleukin-1 Production | POSITIVELY CORRELATED WITH | Inflammatory Response |
| Interleukin-6 Production | POSITIVELY CORRELATED WITH | Inflammatory Response |
| Intercellular Adhesion Molecule 1 | POSITIVELY CORRELATED WITH | Inflammatory Response |
| Vascular Cell Adhesion Protein 1 | POSITIVELY CORRELATED WITH | Inflammatory Response |
| C-Reactive Protein | POSITIVELY CORRELATED WITH | Inflammatory Response |
| Inflammatory Response | CONTRIBUTES TO | Peripheral Vascular Disease |
|---------|-----------|---------|

Reference: 
  - [https://europepmc.org/article/PMC/2716262](https://europepmc.org/article/PMC/2716262)
  - [https://go.drugbank.com/drugs/DB00806](https://go.drugbank.com/drugs/DB00806)
